SOD1 and amyotrophic lateral sclerosis: Many advances have been achieved in the past 5 years, such as applying gene silencing for SOD1 and C9Orf72, developing viable biomarkers for diagnosing patients with ALS with mutations in those genes, and evaluating the efficacy of potential treatments.